NRG-BR001

A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases

Principal Investigator

Steven Chmura

Status

Disease Site

Breast [BR] Breast

Phase

I

Developmental Therapeutics

No

Primary Objective

To determine the recommended  SBRT dose for each of the metastatic locations being treated given the individual and overlapping fields when multiple metastases are treated with SBRT in a national clinical trials network setting.

Patient Population

Oligometastases arising from the breast, lung or prostate; oligometastases defined as ≤ 4 distinct metastases visualized on standard imaging studies; all metastases not resected must be amenable to SBRT; local and regional disease treated per standard of care with no evidence of progression.

 

 

Target Accrual

84